Anixa Biosciences Receives WHO Approval for International Non-Proprietary Name of CAR-T Therapy, Signifying Major Step Towards Global Recognition and Future Market Launch
Approval of Non-Proprietary Name: Anixa Biosciences announced that the WHO's INN Expert Committee approved "liraltagene autoleucel" as the non-proprietary name for its CAR-T therapy targeting recurrent ovarian cancer, marking a significant step towards commercialization.
Ongoing Clinical Trials: The company is currently conducting a Phase 1 trial of liraltagene autoleucel in partnership with Moffitt Cancer Center, focusing on safety and clinical activity in women with recurrent ovarian cancer who have not responded to previous treatments.
Unique CAR-T Technology: Liraltagene autoleucel utilizes a novel chimeric endocrine receptor-T cell (CER-T) technology that targets the follicle-stimulating hormone receptor (FSHR), which is expressed on ovarian cells and certain cancer cells.
Anixa's Broader Portfolio: Anixa is a clinical-stage biotechnology company with a focus on cancer treatment and prevention, collaborating with leading research institutions to develop innovative therapies, including vaccines for breast and ovarian cancer.
Discover Tomorrow's Bullish Stocks Today
Analyst Views on ANIX
About ANIX
About the author
Anixa Secures Mexican Patent for Breast Cancer Vaccine
- Patent Approval: Anixa Biosciences has received a patent allowance from the Mexican Institute of Industrial Property, marking an expansion of its international intellectual property coverage for breast cancer vaccine technology, thereby reinforcing its leadership in cancer immunotherapy.
- Market Opportunities: The patent complements existing patents in the U.S. and other key markets, laying the groundwork for Anixa's future regulatory and commercial efforts in regions with high breast cancer incidence like Mexico.
- Clinical Development Support: The vaccine is based on immunizing against human α-lactalbumin, aiming to selectively activate the immune system to prevent tumor formation, which is expected to improve breast cancer diagnosis and treatment outcomes for women in Mexico.
- Global Strategic Positioning: By strengthening its global patent estate, Anixa is paving the way for future international development and commercialization strategies, potentially partnering with larger pharmaceutical companies for worldwide commercialization.
Anixa Biosciences Declines Following Phase 1 Results for Breast Cancer Vaccine
Anixa Biosciences Phase 1 Trial Results: Anixa Biosciences (ANIX) reported a ~21% drop in stock after sharing phase 1 data for its breast cancer vaccine targeting α-lactalbumin, which showed that 74% of participants achieved immune responses.
Cohorts and Safety Findings: The trial involved 35 participants across three cohorts, with good safety and tolerability noted in the first two cohorts, while the third cohort experienced some Grade 3 adverse events related to injection-site irritation.
Future Trial Plans: Anixa indicated that the phase 2 trial design may include a combination study with Merck's Keytruda in the neoadjuvant setting for newly diagnosed breast cancer patients.
Market Reaction and Context: The market's reaction to the trial results has been cautious, with discussions around the justification of optimism regarding Anixa's upcoming phase 1 readout and other clinical programs.
